A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti-Reference-Cited by-同舟云学术

A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti

Published:2018-08-02 Issue:12 Volume:20 Page:2740-2747
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Guo Lixin¹^ORCID,Chen Li²,Chang Baocheng³,Yang Liyong⁴,Liu Yu⁵,Feng Bo⁶

Affiliation:

1. Department of Endocrinology; Beijing Hospital, National Center of Gerontology; Beijing China

2. Department of Endocrinology; Qilu Hospital of Shandong University; Jinan China

3. Key Laboratory of Hormones and Development, Ministry of Health, Tianjin Key Laboratory of Metabolic Diseases; Tianjin Medical University Metabolic Diseases Hospital; Tianjin China

4. The Endocrinology Department; The First Affiliated Hospital of Fujian Medical University; Fuzhou China

5. Sir Run Run Shaw Hospital of Nanjing Medical University; Jiangsu China

6. Shanghai East Hospital affiliated to Tongji University; Shanghai China

Funder

Merck Serono China Co. Ltd., an affiliate of Merck KGaA, Darmstadt, Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13454/fullpdf

Reference29 articles.